In a landmark study published in Nature on June 22, 2026, researchers at the Innovative Genomics Institute at UC Berkeley, UC San Francisco, and Gladstone Institutes have engineered a CRISPR system called Cas12a2 that can selectively detect and destroy cancer cells by shredding their genetic material, leaving healthy cells completely intact. The approach targets mutations in the p53 tumour suppressor gene — a genetic alteration found in nearly 50% of all cancers and in 70–90% of the most difficult-to-treat cancers, including ovarian, pancreatic, and non-small cell lung cancer.

CRISPR Cas12a2 cancer DNA treatment

How the Technique Works

The research team, led by Dr. Jennifer Zeng and colleagues, reprogrammed the CRISPR-Cas12a2 enzyme — originally discovered in bacteria as an antiviral defence mechanism — to recognise the specific RNA transcript produced only by cells carrying mutated cancer genes. In nature, Cas12a2 acts as a bacterial suicide pill, killing infected cells to prevent viral spread. The engineered version works identically: once it detects a cancer-specific RNA signature inside a human cell, the Cas12a2 enzyme activates and initiates what the researchers call "chromatin shredding" — slicing through all the genetic material within that specific cell. This wholesale demolition triggers cell death through apoptosis, while cells lacking the target RNA sequence show no damage and continue to proliferate normally.

Targeting the 'Undruggable'

The p53 mutation has long been considered "undruggable" by conventional pharmaceutical approaches. Every cell in a cancer patient's body carries the mutation, which means traditional small-molecule drugs that target the altered protein would also harm healthy cells. Cas12a2 solves this problem by targeting the RNA transcript rather than the protein itself. Because the engineered CRISPR system only activates when it finds the specific RNA sequence produced by the mutant gene, it can distinguish between cancerous and healthy cells with remarkable precision. The study demonstrated no off-target activation, even when targeting transcripts with different cellular abundances.

CRISPR Cas12a2 enzyme mechanism

What This Means for Cancer Treatment

Unlike conventional chemotherapy, which causes indiscriminate DNA damage across all rapidly dividing cells — leading to the well-known side effects of hair loss, nausea, and immune suppression — Cas12a2 only induces DNA damage above background levels when cells express the target transcript. In co-culture experiments, targeted cancer cells were eliminated while healthy cells in the same dish remained unaffected and continued dividing. This precision could fundamentally change how certain cancers are treated, particularly those with well-characterised genetic mutations. However, significant challenges remain, including developing safe and effective delivery methods for human patients — the Cas12a2 system currently requires viral vectors to deliver the genetic instructions into target cells.

India Angle: Research and Clinical Implications

India has one of the highest cancer burdens in the world, with an estimated 1.46 million new cases diagnosed annually according to the Indian Council of Medical Research (ICMR). Cancers where p53 mutations are most prevalent — ovarian, pancreatic, and non-small cell lung cancer — are also among the leading causes of cancer-related deaths in India. The Cas12a2 approach could be particularly impactful for Indian patients if the technology advances to clinical trials, given that these cancers are often diagnosed at advanced stages when conventional treatments have limited effectiveness. Indian biotechnology companies and research institutions, including those at the Centre for Cellular and Molecular Biology in Hyderabad and the National Centre for Biological Sciences in Bengaluru, have growing expertise in CRISPR-based therapies and could potentially contribute to clinical translation efforts. The open publication of the research protocol by the IGI team aligns with India's Department of Biotechnology's strategy of fostering open science collaborations in genomic medicine.

Limitations and Next Steps

While the results are promising, the research is currently at the cell culture stage, and human clinical trials remain years away. Key challenges include ensuring delivery specifically to cancer cells throughout the body, preventing immune responses to the CRISPR components, and confirming that cancer cells cannot evolve resistance to the approach. The team noted that targeting multiple RNA sequences simultaneously may help prevent resistance, and combination approaches with existing immunotherapies could be explored. The researchers published their protocol openly to encourage rapid replication and advancement across laboratories worldwide.

Key Findings at a Glance

  • Target: p53 tumour suppressor gene mutation (found in ~50% of all cancers)
  • Mechanism: RNA-triggered chromatin shredding via Cas12a2 enzyme
  • Precision: Zero off-target activity in co-culture experiments
  • Applicability: Ovarian, pancreatic, non-small cell lung cancer (70-90% prevalence)
  • Stage: Cell culture; animal and human trials needed
  • Publication: Nature, DOI: 10.1038/s41586-026-10466-y

Sources